Prediction Case File
YouTubeEvaluation Complete

Reddit, Inc. Stock Prediction and Forecast [RDDT]

1 extracted signal · 1 resolved · 0 still active

StockInvest.us profile imageStockInvest.usIndependent analyst profile
Source published
16 Jan 2026, 04:29 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Reddit, Inc. Stock Prediction and Forecast [RDDT]
Source overview

AI-generated source summary

The analysis of Reddit, Inc. (RDDT) stock, initiated on January 15, 2026, presents a mixed but ultimately negative outlook. The system has ranked RDDT as a Sell Candidate with a score of -4.638. While the stock is currently in a strong short-term rising trend, a further rise is signaled within this trend. However, the overall forecast anticipates weak performance in the short to medium term. The three-month trend indicates a potential 27.67% change with a return range of 20.37% to 45.58%, while the twelve-month analysis projects a 55.76% change, ranging from 14.36% to 108.93%. The last trading day saw the stock close at $228.67, a 9.39% drop from an open of $252.38, with a daily fluctuation of 11.43% between a low of $225.25 and a high of $251.00. Volume increased by 6 million shares despite falling prices, totaling 11 million shares valued at $2.48 billion. The 52-week high was $282.95, and the low was $79.75. Current price is 19.18% below the 52-week high. Technical indicators show a buy signal from the 3-month MACD, but sell signals from pivots (3 days ago), short-term (2 days ago) and long-term moving averages (2 days ago). Bollinger Bands indicate a buy signal (3 days ago). On corrections up, resistance levels are noted at $248.22 and $233.00, with a break above these signaling buy opportunities. Support levels are identified at $208.95, $204.98, and $194.42, while resistance levels are at $231.34, $244.89, $250.89, and $260.12. The weekly volatility is 8.01%, and the risk is classified as medium. The P/E ratio stands at an elevated 123.15, suggesting overvaluation. Insider trading data reveals a negative insider power of -33.445, with insiders selling significantly more shares than they bought over the last 100 transactions. Analyst ratings include Overweight/Hold from Morgan Stanley, Outperform/Initialise from Evercore ISI, Neutral/Initialise from Cantor Fitzgerald, and Buy/Hold from Needham and Jefferies. The overall consensus from analysts is neutral. The next earnings report for Q4 2025 is anticipated on February 11, 2026, with consensus estimates at $0.97. Despite a positive underlying trend, the presence of several negative signals and technical weaknesses leads to a negative evaluation, downgrading the stock to a Sell Candidate, with expected weak performance in the near term.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    1 eligible signal linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Analyst snapshot

StockInvest.us

Platform-wide history, separate from this source evaluation.

Reliability
53.5
Tracked signals
1640
Historical success
42.8%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail